Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial

Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial

To evaluate the safety of the 15-valent pneumococcal conjugate vaccine (PCV15 (by LvZhu & Co. Ltd)) in healthy infants aged 2 months (minimum to 6 weeks) and 3 months old. This phase I clinical trial enrolled 80 subjects in Laishui County, Hebei Province, China. The total population was divided...

Full description

Bibliographic Details
Main Authors: Lu-Lu Pan, Zhao Gao, Wei-Wei Zhou, Min-Jie Li, Wen-Jian Fang, Wen-Juan Ji, Ying Zhao, Lin Du, Yu-Liang Zhao
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
pneumococcal
15-valent conjugate vaccine
safety
phase i clinical trial
Online Access:http://dx.doi.org/10.1080/21645515.2022.2116881

Internet

http://dx.doi.org/10.1080/21645515.2022.2116881

Similar Items